Clinical Trials Logo

Neurodevelopmental Disorders clinical trials

View clinical trials related to Neurodevelopmental Disorders.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT05619224 Enrolling by invitation - Premature Birth Clinical Trials

Physiotherapy to Improve Feeding Skills in Preterm Infants

Start date: February 1, 2022
Phase: N/A
Study type: Interventional

INTRODUCTION: Suction problems are very common in premature children due to a lack of maturation and orofacial control, the manifestation of a low muscle tone and the incoordination during sucking-swallow-breathe. In addition, there are some problems in different systems that get it worse. AIM: compare oral stimulation programme with a neurodevelopmental stimulation intervention programme combined with an oral stimulation programme, evaluating its effectiveness on feeding development, neuromotor development and other aspects of development. METHODOLOGY: we proposed a prospective parallel group clinical trial with two randomized and independent experimental groups. All preterm infants born between 2022-2023 at University Hospital Torrecárdenas, with nasogastric tube and gestational age between 27-32 weeks will be included. EXPECTED BENEFITS: to have better results when the preterm infant is approached globally, also considering the postural situation of the preterm infant. In addition, it is expected that the development of children treated by combining oral stimulation with neurodevelopmental stimulation will be equated or close to healthy and born-to-term child. RESULTS APPLICABILITY: Improved eating performances will reduce length of hospital stay as well as a greater autonomy improving family situation. It will also allow the reduction of hospital costs and the creation of a new way to attend this problem in preterm children.

NCT ID: NCT05381272 Enrolling by invitation - Preterm Birth Clinical Trials

Impact of Early and Severe Fetal Growth Restriction on Neurodevelopmental Outcomes in Preterm Infants

Start date: January 1, 2010
Phase:
Study type: Observational

Very early onset intra uterine growth restriction (IUGR) affects 5-10% of pregnancies and is the second leading cause of perinatal mortality. However, there is few studies on this subject, especially concerning the neurodevelopment outcomes. Objective: to compare neurodevelopmental outcomes at the age of 2 of very preterm infants with antenatal duagnosis of severe and early IUGR in comparison with infants of the same gestational age, same sex and over the same period with no IUGR. Hypothesis : Preterm infants with early and severe antenatal IUGR have more neurodevelopmental delay than infants with no IUGR.

NCT ID: NCT05368493 Enrolling by invitation - Clinical trials for Neurodevelopmental Disorders

Air Pollution and Development in the Boricua Youth Study

Start date: January 23, 2023
Phase: N/A
Study type: Interventional

This study seeks to understand the relationship between prenatal maternal air pollution exposure and offspring risk for ADHD and examine two potential -modifiable- mechanisms: prenatal maternal inflammation and offspring sleep problems. We will employ a longitudinal neuroimaging study design and leverage a well-characterized intergenerational cohort of Puerto Ricans to address prior literature's limitations. This will be the first study to use infant neuroimaging to disassociate the effects of prenatal pollution exposure from those of postnatal pollution exposure, adversity and disadvantage, and offspring genetic risk for ADHD.

NCT ID: NCT04937062 Enrolling by invitation - Clinical trials for Developmental and Epileptic Encephalopathy

Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy

Start date: March 1, 2021
Phase: Early Phase 1
Study type: Interventional

This study is to evaluate the use of glycerol phenylbutyrate for monogenetic developmental epileptic encephalopathies (DEEs). DEEs are characterized by epilepsy and developmental delay in early life. Two examples of DEEs are STXBP1 and SLC6A1, though there are dozens of others. STXBP1 Encephalopathy is a severe disease that can cause seizures and developmental delays in infants and children. SLC6A1 neurodevelopmental disorder is characterized by developmental delay and often epilepsy. Both STXBP1 encephalopathy and SLC6A1 neurodevelopmental disorder cause symptoms because there are not enough working proteins made by these genes. It is possible that a medication called phenylbutyrate may help the the remaining proteins work better for STXBP1, SLC6A1, and/or other similar DEEs caused by single genes (i.e. "monogenetic"). This study is to test if glycerol phenylbutyrate is safe and well tolerated in children with monogenetic DEE.

NCT ID: NCT02871674 Enrolling by invitation - Clinical trials for Attention Deficit Disorder With Hyperactivity

Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial

Start date: October 2016
Phase: N/A
Study type: Interventional

The study aims to implement and evaluate an RCT of behavioural sleep interventions for children aged 5-12 years with ADHD, and their primary caregivers, (women) in Saudi Arabia to address the following questions: 1. To what extent can a behavioural intervention improve sleep difficulties and increase sleep duration in children with ADHD? 2. To what extent do intervention-induced changes in sleep for children or primary caregivers (women) account for any changes in ADHD symptoms?